Ensign Peak Advisors, Inc Cytokinetics Inc Transaction History
Ensign Peak Advisors, Inc
- $51.2 Billion
- Q1 2025
A detailed history of Ensign Peak Advisors, Inc transactions in Cytokinetics Inc stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 31,796 shares of CYTK stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,796
Previous 296,835
89.29%
Holding current value
$1.18 Million
Previous $14 Million
90.85%
% of portfolio
0.0%
Previous 0.03%
Shares
19 transactions
Others Institutions Holding CYTK
# of Institutions
400Shares Held
128MCall Options Held
3.66MPut Options Held
900K-
Black Rock Inc. New York, NY14.7MShares$546 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$441 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.96MShares$370 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA7.99MShares$297 Million0.06% of portfolio
-
State Street Corp Boston, MA6.09MShares$226 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $3.5B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...